ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
ADMA Biologics, Inc.NASDAQ: ADMA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $1.78M fell 13.5% year over year, behind the -2.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.
Context
- Depreciation & amortization amounted to 1.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of -2.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 8.1M USD
- Year-over-year change
- +0.6%
- 4-year CAGR
- +10.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.1M | +0.6% |
| FY2024 | 2024-12-31 | 8.05M | -3.4% |
| FY2023 | 2023-12-31 | 8.33M | +17.1% |
| FY2022 | 2022-12-31 | 7.11M | +29.4% |
| FY2021 | 2021-12-31 | 5.5M | — |
Depreciation & Amortization vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.8% is the 2nd highest of 4, against a peer median of -21.3%.
- Depreciation & amortization amounts to 1.5% of revenue for ADMA, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €443.93M EUR | +1.5% | +1.7% | 6.0% | |
| LTM Jun 2026 | $7.69M USD | -2.8% | +4.4% | 1.5% | |
| LTM Mar 2026 | $1.88M USD | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.07M USD | -21.3% | -36.6% | 0.6% | |
| Peer median (excluding ADMA) | — | -21.3% | +1.7% | 3.4% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| Deferred Income Tax | 220.76K | 0 | 0 | (84.28M) | 11.02M |
| Stock-Based Compensation | 3.49M | 5.22M | 6.19M | 13.62M | 20.03M |
| Change in Working Capital | (51.68M) | (18.29M) | (10.12M) | (18.54M) | (139.6M) |
| Accounts Receivables | (15.34M) | 13.07M | (11.92M) | (22.58M) | (108.43M) |
| Inventory | (43.19M) | (38.56M) | (9.63M) | 2.67M | (36.23M) |
| Accounts Payables | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M |
| Other Working Capital | 5.49M | 6.4M | 7.58M | (2.78M) | 2.74M |
| Other Non-Cash Items | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M |
| Operating Cash Flow | (112.37M) | (59.51M) | 8.8M | 118.67M | 50.4M |
| Capital Expenditures | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (22.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (210K) | (349K) | (316K) |
| Investing Cash Flow | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (21.89M) |
| Debt Repayment | (34K) | 51.71M | (23.6M) | (60M) | (3.18M) |
| Common Stock Issued | 121.14M | 64.65M | 0 | 7.49M | 2.98M |
| Common Stock Repurchased | 0 | 0 | (1.42M) | 0 | (31.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (62K) | (7.51M) | (13.97M) | (5.8M) | (11.89M) |
| Financing Cash Flow | 121.05M | 108.85M | (38.99M) | (58.3M) | (44.02M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.83M) | 35.43M | (35.17M) | 51.8M | (15.52M) |
| Free Cash Flow | (125.88M) | (73.42M) | 3.82M | 110.1M | 27.82M |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.